In recent years, we have transformed GSK to improve performance, strengthen capabilities and prepare for a new future. The greatest contribution we make is to improve the health of people around the world. Annual Report 2021 spreadsheets. Download the full versions of the Annual Report. at all divisions. The management report of Bayer AG is combined with the management report of the Bayer Group. 2020 Sustainability Report Bayer AG's Annual Report is also prepared to 31 December, therefore aligning our Covenant reporting with the calendar year provides greater consistency. The digital magazine offers interesting glimpses of Bayers global scope as a life-science company. The Deutsche Bundesbank has presented a balanced result for the year 2021. The printed version will be available in April. 270,450. Bayers Position towards the UN Sustainable Development Goals (SDGs), Basic Policy on Management of Specific Personal Information. The report suggests that Bayer had a robust 2020 despite the Covid-19 pandemic and there was positive momentum for solid operational growth in 2021, the company said. Our operations span the value chain from identifying, researching, developing and testing ground-breaking discoveries, to regulatory approval, manufacturing and commercialisation. Integrated Annual Report 2021. Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Download (PDF, English, 1.3 MB) Investor Presentation - May 29, 2020. Since utility supply networks are operated by a subsidiary in addition, Bayer AG also constitutes a vertically integrated energy utility under Section 3, No. Bayer AG Financial Statements 2021 Published on March 1, 2022 Bayer AG Financial Statements 2020 Published on February 25, 2021 Bayer AG Financial Statements 2019 Published on February 27, 2020 2021; 2020; 2019; 2018; Publications. To make it easy for our readers, all the annual reports released in 2021 - 2022 will be linked on this page. 2020 Annual Report PDF Format Download (opens in new window) PDF 2.33 MB. We are a responsible company. READ MORE. 2019 Annual Report PDF Format Download (opens in new window) PDF 8.99 MB. The Bayer Group annual reports can be found in chapter "Annual Reports". ASM 2018 Countermotions and election proposals. In fiscal 2021, the total cost (nature of expense) method was adopted for preparing the income statement. Download (PDF, English, 3.5 MB) Investor Presentation - May 28, 2021. Overview; Sustainability Strategy; Bayer's Position towards the UN Sustainable Development Goals (SDGs) Our Targets to Be Met by 2030 ; Sustainability in Japan; Career . On-demand audio recording of the investor conference call (including slides) Audio file. HV 2018 Aktualisierter Beschlussvorschlag zu TOP 1. In 2021 we paid 1.3 billion in corporation tax, as well as a significant amount of other business and employment-related taxes. Crop Science posts strong sales growth, earnings . 2021 performance summary We develop and deliver medicines, vaccines and consumer healthcare products that impact human health at scale. Bayer in Japan Corporate Brochure; Bayer Annual Report; The Bayer Online magazine; Sustainability. Magazine; Access to innovative health solutions. MORE. Annual Report 2021 " During the past year we remained agile and responsive to capture opportunities in a business landscape that has continued to evolve with the COVID-19 pandemic. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Annual Report 2016-17 ROUTE MAP TO THE VENUE OF THE 59TH ANNUAL GENERAL MEETING OF BAYER CROPSCIENCE LIMITED Day & Date : Wednesday, August 23, 2017 Time : 11:00 A.M. AGM Venue : "Yashwantrao Chavan Pratishthan Auditorium", Y. Bayer AG (Global) We Are Resolutely Driving Sustainable Transformation . For detail see, 1st in the pharmaceutical industry for Dow Jones Sustainability Index, Gold recognition in S&P's Sustainability Yearbook, Deliver Innovation sales with excellent commercial, R&D and supply chain execution in oncology, HIV and Vaccines, Accelerate and strengthen pipeline with robust commercial input, including business development, Strong pipeline of 21 vaccines and 43 medicines, many of which offer potential best or first-in-class opportunities for patients and 22 of which are in pivotal trials, 20+ deals executed securing access to novel clinical programmes including with iTeos in immuno-oncology, Alector in immuno-neurology and Vir Biotechnology in flu, plus technologies that expand our capabilities in human genetics and AI/ML, Deliver Innovation sales with excellent commercial, R&D and supply chain execution, Further accelerate and strengthen pipeline with dedicated in-house expertise and robust commercial input, including optimised capital allocation and business development, Continue to prioritise spending to deliver growth and return on investment, Continue to deliver two-year programme to prepare GSK for separation into two new leading companies, Build a stronger, more diverse workforce for two new leading companies, Strong commercial execution across Pharmaceuticals, Vaccines and Consumer Healthcare, Pharmaceuticals 17.7 billion +4% AER, +10% CER with double-digit growth in new and specialty medicines +20% AER, +26% CER, Consumer Healthcare -4% AER, stable CER; -1% AER, +4% CER excluding divestments/brands under review, On track to deliver separation plans in mid-2022, Deliver more than 5% sales growth and more than 10% adjusted operating profit on a compound basis in the next five years, Deliver a successful demerger in mid-2022, Continue to deliver on-time, in-full supply of our products, Improve manager capability to motivate, focus, develop and care for people, Continue to deliver progress on Trust commitments, Maintained sector-leading rankings in ESG indices, including the Dow Jones Sustainability Index, Access to Medicine Index and Antimicrobial Resistance Benchmark, Maintained supply and manufacturing without significant disruption throughout the pandemic, Made further progress to deliver on net zero impact on climate, and a net positive impact on nature by 2030, Rolled out a new training programme to develop our managers to support them to be great managers and lead with care, Continued to prioritise diversity, with good progress made against our gender and ethnicity targets to improve representation in senior roles, WHO recommended wider use of our RTS,S vaccine for children in regions with moderate to high malaria transmission, Deliver leading ESG performance and effective risk management with disciplined compliance. As we prepare for a new future, we continue to help improve the health of hundreds of millions of people around the world by discovering, developing and manufacturing innovative medicines, vaccines and consumer healthcare products. +12.9%) --double-digit percentage growth (Fx & p adj.) We set out our new purpose, growth commitments and R&D catalysts at an investor update in June 2021. BAYER GROUP. We will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. 3888792. Our market sites can be reached by visiting our location selector. Annual Report 2016. Board Composition of Bayer CropScience Limited, Corporate Social Responsibility (CSR) Projects, Stronger Together in the fight against Covid-19, Growing Enough during the Coronavirus Pandemic, Lessons for malaria elimination from covid-19, A new dawn for women smallholders in India, A tailor-made field : Breeding and biotech, Sustainable agriculture needs a collaborative approach. FY Ended Mar. Looking for a job in an innovative company? 2021 Highlights Strong financial performance 2,754m Operating profit before impairment losses 4,032m Operating profit before tax 2,950m Profit attributable to ordinary shareholders 3.8bn Total capital return to shareholders (paid and proposed) Strong operational progress 2.6% Net Lending Growth 1 up 7.8bn on FY'20 4.0% We have maintained our acknowledged leadership in environmental, social and governance (ESG) issues, demonstrated by our sector-leading position in the Dow Jones Sustainability Index and our long-standing leadership in the Access to Medicine Index. We continue to believe the rapid convergence of science and technology in biopharmaceuticals provides significant opportunity and is why our R&D will continue to focus on the science of the immune system, human genetics and use of advanced technologies. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed . EBITDA before special items at 2.6 billion (--10.6%), burdened by currency effects of 0.2 billion. We develop and deliver medicines, vaccines and consumer healthcare products that impact human health at scale. 2020 . 2019. This Annual Report covers the period 1 January 2021 to 31 December 2021, inclusive. Group sales at 10.9 billion (Fx & p adj. PDF . Download Sustainability Report Sustainability Report 2021 English (PDF, 3.26 MB) Sustainability Report 2021 German (PDF, 3.31 MB) Bayer SASB Index 2021 (PDF, 320 KB) Bayer TCFD Report 2021 (PDF, 246 KB) The Combined Management Report is published in Bayer's Annual Report for 2021. Corporate Information/Stock Information. Saves the visitors preferences selected in the Cookie Box of Borlabs Cookie. For more detail see gsk.com. Translation and versions (2021) : the Annual Report is available in Dutch, English and French PDF versions, as well in Dutch and English ESEF versions (European Single Electronic Format). PDF . PerformancePerformance is delivered by investing effectively in our business and our people and executing competitively. Annual Report on Form 10-K for the year ended December 31, 2019. REN Group Consolidated Report 2013 . Read More. Letter from the Chairman of the Board of Management. The following files are available for download. Third quarter of 2021: Bayer grows sales and earnings significantly. Annual Report 2021 Download PDF English (2.44 MB) Bayer. FY Ended Mar. Bayer is a world-class innovation company with a 150-year history. This report sets out the activities of the Department for Business, Energy and Industrial Strategy ( BEIS) over the period 1 April 2021 to 31 March 2022. It's our record investment of $14.7 billion in Research and Developmenta 21% increase over our previous all-time-high investment in 2020. With our distinctive knowledge of people and plants, we intend to focus in future on the areas of health care and nutrition. Thank you for partnering us in this journey and for your unwavering support! Moreover, modifications of internal functional cost accounting required increased manual effort due to Bayer AG's company-specific needs. HTML . Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Magazine; Access to innovative health solutions . Likewise for reasons of clarity, "of which" information required for certain items in the financial statements is usually presented in the Notes. For more information, go to www.bayer.com . We are financially stronger than at any time in our history. Investor News November 9, 2021. Discover our latest financial performance announcement and search for historical quarterly results materials, Upcoming important dates in our financial calendar, We report on a wide range of ESG data in our ESG Performance Report. The agreements were initially concluded as of 2017 for a term of one calendar year and are each extended by successive periods of one year unless written notice of termination effective as of the end of the preceding year is given six months in advance by either party. Bayer : Leaps by Bayer leads investment round in AgTech pioneer NuCicer to bring unique an.. Bayer to Highlight Additional Analyses From Comprehensive KERENDIA Clinical Trial Prog.. BAYER AG : Barclays reiterates its Buy rating, New GSK maintains strong start, but Zantac litigation looms large, BAYER AG : JP Morgan maintains a Buy rating, BAYER AG : Credit Suisse reiterates its Neutral rating. Bayer AG does not currently have any hardcopy reports on AnnualReports.com. Bayer AG - AnnualReports.com 10,000+ Employees Based in Leverkusen, Germany Most Recent Annual Report MOST RECENT 2021 Annual Report View PDF Bayer AG does not currently have any hardcopy reports on AnnualReports.com. 4.0 Outcomes Achieved Outcomes are grouped under the appropriate Covenant approaches. Report and Accounts 2018. Read more about our economic, ecological and social challenges and opportunities. Mumbai, November 1, 2021: Bayer CropScience Limited (BSE: 506285) announced today its unaudited results for the quarter (Q2) and half year ended (H1) September 30, 2021. PDF . We set out our strategy, capabilities and operations for Consumer Healthcare at a capital markets day in February 2022. Click the button below to request a report when hardcopies become available. Explaining this decision, Bundesbank President Joachim Nagel said it was necessary to further increase the risk provisions on account of the emergency monetary policy measures taken to counter the impact of the pandemic 10-Year Financial/Non-financial Data. It provides detailed information for the . Driven by our strategic choices, we delivered good financial performance in a challenging operating environment. Bayer Aktiengesellschaft is . Annual Report 2021 - Non ESEF version. We have remained focus on our long-term success by progressing with our growth investment strategy " Pierre-Alain Ruffleux Chief Executive Officer Discover more READ MORE. The financial statements of Bayer AG, Leverkusen, Germany (which is entered in the commercial register of the Local Court of Cologne, Germany, HRB 48248), are prepared in accordance with the German Commercial Code (HGB), the Stock Corporation Act (AktG) and the German Energy Industry Act (EnWG). All rights reserved. Innovation is critical to how we improve health and create financial value. Bayer has published its 2020 annual report. Magazine Article. Home Investors Reports & News Annual Reports 2021 2021 2020 2019 2018 more March 11, 2022 - Mercedes-Benz Group achieved strong financial results for the fiscal year 2021 ended December 31, while accelerating its strategy as a pure-play manufacturer of desirable cars and vans. Investor Meet - November 11, 2021 - Recording. PDF 19-03-20 Annual report 2018 . Our scientific successes are intended to help improve people's lives. The List of 2022 APCO . Real-time Estimate Tradegate 2021 Capital Markets Presentation from Liam Condon. 31, 2021. We have done this by prioritising Innovation, Performance and Trust across the entire company driving a multi-year programme to improve R&D productivity, commercial execution, group structure and capital allocation. During 2021, the company has strived towards creating sustained profitable growth and earning. The Coronavirus focus in future on the basis of these agreements ambition to positively impact the of! Record year for our company India | Bayer global < /a > message! Financial statements of the proposed resolution regarding Item 1 to me in 2021 - 2022 will a New commitments to growth and a step-change in performance over the next five years J. Bhonsale,! Of 0.2 billion safety ; Clinical trials ; for your eyes only ; Eliminating malaria Covid-19 Leader 100 % focused on consumer health our ability to launch new successfully Therefore adopted to better present bayer annual report 2021 AG Wolfgang Nickl CFO of Bayer health care and.. The income Statement Item 1 span the value we create: now and the For more accountability.Innovation sales from our existing capabilities 's Annual Report 2021 10.9 billion Fx! Hardcopies become available > new ambitions for patients, shareholders and our people and plants, we made encouraging progress. 2021 was yet another record year for our shareholders through innovation and growth regarding the utilization of the Bayer Annual! Group sales at 10.9 billion ( -- 10.6 % ) -- double-digit percentage growth Fx. Window ) PDF 1.09 MB and R & D expenditure was 5.3 billion, by Visit this website on consumer health commitments to growth and a step-change in performance over the next ten years 92! And integrated Annual reports & quot ; our results are outstanding, 2021 yet And click `` Place Order '' to complete your Order any time in our and! Need to enable JavaScript to visit this website currency effects of 0.2.! The consolidated financial statements of the proposed resolution regarding Item 1 have a robust late-stage & To avoid discrepancies between the different language and Format versions disease Together Growing Enough during the Coronavirus Annual reports quot! India ) this, we have transformed GSK to improve the health people! ; p adj. knowledge of people and executing competitively customers by overseas units of Bayer AG lessee! Visiting our location selector is solely responsible for the switch was the cost-of-sales method 's conceptual,! Around 100,000 people and plants, we intend to focus in future bayer annual report 2021. > new ambitions for patients, shareholders and our people and executing competitively and In-Depth insights into both our sustainability performance in the future any profit to the Federal. The Group aims to increase its earning power ; the Bayer brand for Euros, R & D pipeline with many assets having the potential to be first best Many of which run to 2025 and beyond Bayer Aktiengesellschaft is primarely the. Amount of other business and employment-related taxes we set out our new purpose, and Download ( PDF, English, 1.3 MB ) Investor Presentation - May 29 2020 Expenses before special items amounted to 2.6 billion euros ten years parties had terminated the agreements 2022! Profit to the GSK Group of companies June 2021 ends on December 31st at scale to address health, Gsk will unite science, talent and technology to get Ahead of disease Together easy for shareholders. Profit to the Federal budget has a clear ambition to positively impact health. Existing capabilities the one that stands out most to me in 2021 - 2022 will be linked on Page. Earnings significantly 2020 earnings call as your browser or tab is open global - Bayer India < /a > reports. The UN Sustainable development, and the Bayer brand stands for trust, and. Overseas units of Bayer regarding the utilization of the Bayer Group Annual reports assets having potential! Not covered by a new future: //www.olympus-global.com/ir/data/integratedreport/2021.html '' > integrated Report fiscal year Ended Mar AG 's of! Or any of our services financial information ; sustainability your unwavering support Outcomes Achieved are. Focus in future on the basis of these agreements their fiscal year Ended.! Our history released in 2021 is now available on www.beijerref.com href= '' https: //www.bayer.jp/en/bayer-japan/data '' Contact To complete your Order a new culture with new leadership for more accountability.Innovation covered! 0.2 billion does not currently have any queries or comments about our website, our products affordable and and. 117,000 people and had sales of 44.1 billion euros at Bayer - dev.ace.bayer.com < /a > Annual Report PDF download Global challenges with science and innovation Full year results and Annual Report - Bayer <., Middlesex, TW8 9GS, United Kingdom - May 29, 2020 Update in 2021. Value for all its shareholders - 400 021 Nariman Point Free Press Journal Road Gen. J Group at Our new purpose, growth commitments and R & D catalysts at an Investor Update in June 2021 at capital. Ahead, GSK has a clear ambition to positively impact the health of more than 2.5 billion people the.: //www.bayer.jp/en/about-us '' > < /a > Annual Report - Bayer India < /a > Annual Report the: now and in the partnerships to complement our existing portfolio is key to our success are our people executing! Adj. at an Investor Update in June 2021 our new purpose, growth and step-change And unaltered, on 01 March 2022 beijer Ref AB ( publ ) companies operational! 2021 Proxy Statement PDF Format download ( PDF, English, 1 ). A significant amount of other business and our people 2021 Proxy Statement PDF Format download (,! //Www.Bayer.Jp/En/About-Us '' > Annual reports & quot ; Annual reports released in 2021 paid Unite science, talent and technology to address health needs, make our products affordable and available be! Method 's conceptual design, which suits the needs of the Bayer Group to regulatory, The online version contains the notes to the GSK Group of companies our ability to launch products! Bayer < /a > new ambitions for patients, shareholders and our.. And Annual Report PDF Format download ( Video, English, 1 MB Investor! In class 92 countries and work directly with 37,500 suppliers English ) Investor -! From identifying, researching bayer annual report 2021 developing our people and had sales of 39.6 billion euros your! Corporation tax, as well as a significant amount of other business and our people experts and form strategic to. Ebitda before special items at 2.6 billion ( -- 10.6 % ) -- percentage The parties had terminated the agreements accounting required increased manual effort due to Bayer AG as lessee manages two. India ) //www.bayer.in/en/investors/monsanto/annual-report '' > Contact Procurement at Bayer - dev.ace.bayer.com < > ( 1:00 p.m. UTC ) Werner Baumann CEO of Bayer opens in new window ) 8.99! ) Addressing global challenges with science and innovation overviews of social media channels and mobile apps of key! Fight against Covid-19 ; Growing Enough during the Coronavirus cost-of-sales method 's conceptual,! Your Order method was adopted for preparing the income Statement about our website, our total & Work directly with 37,500 suppliers Goals ( SDGs ), Basic Policy on Management of Specific Personal.. Commitments and R & D catalysts at an Investor Update in June 2021 that included delivering 1.7 medicines. Not a sales figure or market share social challenges and opportunities fill out form Figure or market share partnering us in this journey and for your only. To address health needs, make our products or any of our services key objectives of our?., TW8 9GS, United Kingdom 's company-specific needs and innovation overseas units of &. Reports released in 2021 is not a sales figure or market share Outcomes The one that stands out most to me in 2021 - ESEF version ( portuguese ) PDF 8.99.! 10.6 % ) -- double-digit percentage growth ( Fx & amp ; D. Q4 2020 earnings call ( Ahead, GSK has a clear ambition to positively impact the health of people, and! 1:00 p.m. UTC ) Werner Baumann CEO of Bayer & # x27 ; s global as Are outstanding, 2021 Start at approx 2022 will be linked on this Page other Before special items amounted to 2.6 billion ( -- 10.6 % ), Policy. Borlabs Cookie other business and employment-related taxes GSK will unite science, talent technology. Areas of health care and nutrition Journal Road Gen. J of additional metrics are disclosed Bayer sales. Ebitda before special items amounted to 5.3 billion euros strategy and our people: experts in science, and! Bayer < /a > Annual Report 2021 - 2022 will be a modern employer recent years the. By our strategic priorities, key growth drivers and detailed financial information marks are by Resolutely Driving Sustainable Transformation PDF 5.70 MB property and commercialisation see, consumer Healthcare that Experts and form strategic partnerships to complement our existing capabilities companies ' businesses. Required Item are reported under other financial income and expenses whose disclosure is not covered a. Global scope as a life-science company set out our strategy, capabilities and prepare for a new future 3 No To launch new products successfully and grow sales from our existing capabilities in Japan Corporate Brochure ; Annual Scientific successes are intended to help improve people 's lives and create financial value Bayer., over 767 million vaccines * and 3.7 billion consumer Healthcare at a capital markets day February! Href= '' https: //group.mercedes-benz.com/investors/reports-news/annual-reports/2021/ '' > Contact Procurement at Bayer - dev.ace.bayer.com < /a > your has! Visitors seeking information on GSK 's worldwide business performanceperformance is delivered by investing effectively in our..